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CONCLUSION: Using change scores responding to a
one-level improvement of PtGA or PhGA or using the av-
erage difference of change between any two levels im-
provement of PtGA or PhGA, the clinically meaningful
improvement for WOMAC pain, stiffness, physical func-
tioning, and total WOMAC scores were approximately
2, 1, 7, and 10, respectively.
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HRQoL measures are becoming important for evaluating
the effects of arthritis treatments. Interpreting changes in
HRQoL scores, however, has not been fully evaluated. 
OBJECTIVE: To determine the clinically meaningful im-
provement of HRQoL as measured by the SF-36 among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
SF-36 and Patient Global Assessment (PtGA) were admin-
istered to patients at baseline and week 12. PtGA was
measured on the following 1- to 5-point scale: very good,
good, fair, poor, or very poor. Change scores were com-
puted by subtracting patient’s baseline from week 12 fol-
low-up scores. Clinically meaningful improvement was es-
timated as the mean change score corresponding to a one-
level improvement in PtGA. A similar interpretation of
clinically meaningful changes was also performed using
physician-global assessment, pain, and functional-status. 
RESULTS: At week 12, the following patients experi-
enced improvements in their PtGA rating: one-level
(1158), two-levels (745), three or more levels (311),
which corresponded to standardized physical and mental
component scores (PCS & MCS) improvements of: one-
level (3.8 and 1.4), two-levels (8.3 and 2.7), and three or
more levels (10.4 and 4.2), respectively. The clinically
meaningful improvement based on PtGA among OA pa-
tients were approximately 3.8 and 1.4 for PCS and MCS,
respectively. The clinically meaningful changes for eight
SF-36 domains were 7.2 for physical function, 13.1 for
role physical, 11.6 for bodily pain, 2.1 for general health,
5.6 for vitality, 6.2 for social function, 7.7 for role emo-
tion, 2.7 for mental health. 
CONCLUSION: Clinically meaningful improvement var-
ies between SF-36 domains and summary scores among
OA patients. These results provide guidance in interpret-
ing HRQoL results and planning clinical trials.
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Given the widespread use of NSAIDs and its association
with gastric injury, the patterns and costs of gastric toxic-
ity are of interest. 
OBJECTIVE: The goal of this study was to describe the
prevalence of concomitant antiulcer medication with
NSAIDs. 
METHODS: We identified patients diagnosed with os-
teoarthritis (OA) (ICD-9 codes: 715, 721.0, 721.3,
721.9), rheumatoid arthritis (RA) (ICD-9 codes: 714.0,
714.1, 714.2, 714.9) or both (OA/RA) between 1992
and 1997 using a managed care claims database. Study
participants had at least 12 months of continuous health
coverage (including drug benefits). We examined initial
NSAID choice and the prevalence of concomitant gas-
trointestinal (GI) drug use (H2 antagonists [H2], proton
pump inhibitors [PPI], prostaglandins [PS]) during the
study period. 
RESULTS: Among NSAID users (n  40,350), ibuprofen
(28.6%) and naproxen (18.2%) were most likely to be
prescribed initially. Antiulcer medication use was more
prevalent in patients receiving NSAID therapy, appeared
to increase with age and vary by diagnosis: rates varied
from 19.1% (OA), 19.6% (RA), 34.3% (OA/RA) in pa-
tients aged 18–39 to 29.2%, 32.3%, and 40.0% in pa-
tients aged 70–79. Fifteen percent of patients had a con-
comitant GI prescription added to their therapy within
60 days after the first NSAID prescription. Most of the
anti-ulcerant use was H2 (76.9%), although PPI use
(10.7%) and PS use (12.4%) increased in latter years. 
CONCLUSIONS: We found that the prevalence of GI
therapy varied by age and diagnosis and that concomi-
tant GI medication use began soon after the initiation of
NSAID therapy.
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The West Virginia Medicaid’s (WVM) prior authoriza-
tion (PA) policy for NSAIDs is expected to produce sav-
ings to the WVM for two reasons: 1) NSAIDs are among
the most frequently utilized drugs in WVM, and 2) while
prices for NSAIDs vary substantially, most of the pre-
scribed NSAIDs are the expensive ones. However, a con-
cern arises whether the anticipated savings of policy im-
plementation may be offset by increased costs of
substitutable drugs and/or medical services. It is also im-
